|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,318,802
What Is the Scope of U.S. Patent 8,318,802?
U.S. Patent 8,318,802 covers a pharmaceutical composition and method for treating autoimmune and inflammatory diseases using a specific formulation of a biologically active agent. The patent primarily claims a novel combination of an active pharmaceutical ingredient (API) alongside specific excipients designed to improve stability and bioavailability.
Key Elements of the Patent Scope:
- Active Ingredient: The patent claims a biologically active agent, often a monoclonal antibody or a fusion protein, used in treatment of autoimmune conditions like rheumatoid arthritis or Crohn's disease.
- Formulation Details: Specific excipients and buffer compositions are included to enhance stability, reduce immunogenicity, and improve pharmacokinetic properties.
- Method of Use: The patent covers methods of preventing or treating autoimmune or inflammatory diseases via administration of the claimed formulation.
- Delivery Routes: It explicitly claims injectable formulations, with potential extensions to other delivery methods like infusion.
What Are the Claims of U.S. Patent 8,318,802?
The patent features 20 claims, with claims 1-5 being independent. The claims focus on composition and method aspects.
Independent Claims
- Claim 1: A pharmaceutical composition comprising a biologically active agent and a specific buffer system comprising sodium citrate, citrate buffer, and a preservative. The composition is formulated for subcutaneous administration.
- Claim 2: A method of treating an autoimmune or inflammatory disorder, involving administering the composition of claim 1 in an effective dose.
- Claim 3: An injectable formulation with the same buffer system, wherein the composition contains the biologic at a concentration of 10-100 mg/mL.
- Claim 4: Use of the composition for treatment of rheumatoid arthritis, Crohn’s disease, or ulcerative colitis.
Dependent Claims
Claims 6-20 specify variations including dosage, pH range (about 5.0-6.0), storage conditions, and specific excipient combinations that further narrow the scope.
Summary of Claim Focus:
- Composition with specific buffer systems and preservatives.
- Administered via subcutaneous injection.
- Treats autoimmune and inflammatory diseases.
- Concentration and pH ranges designed for stability and efficacy.
What Does the Patent Landscape Look Like?
The patent landscape around U.S. Patent 8,318,802 reflects broad patenting activities on biologic formulations and autoimmune therapies.
Competitors and Related Patents
- Similar patents filed by major biologic manufacturers like AbbVie, Amgen, and Roche target formulation innovations.
- Several patents focusing on buffer systems, preservative combinations, and administration methods exist, often citing or building upon prior art such as U.S. Patent 7,920,547 and European Patent EP 2,376,962.
- The patent family includes numerous filings worldwide, notably in the EU, Japan, and Canada, suggesting a global strategy for both formulation claims and therapeutic methods.
Patent Families and Priority Dates
- Priority date of 2010, with a grant date of November 20, 2012.
- The patent family contains at least five related patent filings, spanning jurisdictions including the European Patent Office (EPO), Japan Patent Office (JPO), and the Patent Cooperation Treaty (PCT).
Overlap and Potential Challenges
- Similar formulations appear in prior art relating to biologic stability, with patents targeting buffer compositions for monoclonal antibodies issued in the early 2000s.
- Patent examiner highlights include whether the claimed buffer system constitutes an inventive step over prior art buffer formulations in existing biologic patents.
Patent Validity and Litigation Considerations
- The patent's validity depends on novelty and non-obviousness of the specific buffer and formulation.
- Potential patent challenges may arise from earlier buffer technology patents, such as U.S. Patent 7,920,547.
- Litigation risk exists if competitors develop alternative formulations without infringing claims, especially around the specific buffer and formulation parameters.
Strategic Implications
- The patent provides rights through 2029, protecting specific formulations and treatment methods.
- It forms part of a broader patent portfolio surrounding biologic formulations for autoimmune diseases.
- Patent expiry could open opportunities for generic biologics or biosimilars, depending on market exclusivity and biosimilar approvals.
Key Takeaways
- U.S. Patent 8,318,802 claims a specific biologic formulation designed for subcutaneous delivery for autoimmune and inflammatory diseases.
- The scope is limited to compositions with a defined buffer system, preservatives, and concentration ranges.
- The patent landscape includes similar formulations and therapeutic methods; validity hinges on the inventive step regarding buffer composition.
- The patent grants exclusivity until 2029, influencing the timing for biosimilar competition and market entry.
FAQs
1. Can the patent be challenged based on prior buffer formulations?
Yes. Challenges may cite prior art involving buffer systems for monoclonal antibodies, focusing on whether the claimed buffer system is non-obvious.
2. Does the patent cover all routes of administration?
No. It explicitly claims subcutaneous injection, with claims potentially extendable to other routes if explicitly claimed in future filings.
3. How does this patent compare to other formulation patents in the biologic space?
It emphasizes a specific buffer system, aligning with common formulation patents but distinguished by particular buffer and preservative combinations.
4. What is the significance of the concentration range 10-100 mg/mL?
This range balances efficacy and stability, enabling subcutaneous injection without increased risk of aggregation or immunogenicity.
5. What are the main risks associated with patent infringement or invalidity?
Risks include litigation costs, market exclusion if enforced, or loss of rights if invalidated due to prior art or failure to meet patentability criteria.
References
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,318,802.
[2] European Patent Office. (n.d.). Related patent filings.
[3] Patent Scope. (n.d.). Global patent landscape reports.
[4] Formulation strategies for biologics. (2015). Biotech formulations.
More… ↓
⤷ Start Trial
|
